Radiopharmaceuticals Market to Reach US$ 19.69 Billion by 2033 at 10.8% CAGR; North America Leads with 41% Share | Key Players Novartis, Bayer, Eli Lilly

The Radiopharmaceuticals Market reached US$ 7.91 billion in 2024, rising from US$ 7.20 billion in 2023, and is expected to reach US$ 19.69 billion by 2033, growing at a CAGR of 10.8% during the forecast period 2025-2033. The market is expanding steadily as radiopharmaceuticals play an increasingly important role in diagnostic imaging and targeted therapy, particularly in oncology, cardiology, and neurology.

Growth is driven by the rising prevalence of cancer and chronic diseases, increasing adoption of nuclear medicine procedures, and advancements in radioisotope production and radiolabeling technologies. Expanding applications of theranostics, improved PET and SPECT imaging techniques, and growing investments in personalized medicine are further supporting market growth. Despite challenges related to short isotope half-lives and complex regulatory requirements, continuous innovation and expanding clinical use are strengthening market momentum.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/radiopharmaceuticals-market?sai-v

Radiopharmaceuticals Market is the global market for radioactive drugs used in nuclear medicine for diagnostic imaging and targeted therapeutic applications.

Key Developments
✅ January 2026: In the United States, nuclear medicine and pharmaceutical companies expanded production and clinical adoption of radiopharmaceuticals for oncology, cardiology, and neurology, with growing use of targeted radioligand therapies and PET imaging agents.

✅ January 2026: In Japan, healthcare providers and pharmaceutical firms advanced the use of diagnostic and therapeutic radiopharmaceuticals, supported by investments in cyclotron infrastructure and isotope supply reliability.

✅ January 2026: In Europe, regulatory approvals and reimbursement support accelerated adoption of radiopharmaceuticals in cancer diagnosis and targeted treatment, particularly in precision oncology applications.

✅ December 2025: In the United States, companies strengthened domestic radioisotope production and distribution capabilities to improve supply chain resilience and reduce dependency on imports.

✅ December 2025: In Japan, collaborations between research institutes and pharmaceutical companies focused on developing next-generation radiopharmaceuticals with improved targeting and safety profiles.

✅ December 2025: In Asia-Pacific, expanding access to nuclear medicine facilities drove increased demand for diagnostic radiopharmaceuticals across emerging healthcare markets.

Mergers & Acquisitions
✅ January 2026: In the United States, a pharmaceutical company specializing in nuclear medicine acquired a radiopharmaceutical development firm to expand its oncology-focused radioligand therapy pipeline.

✅ December 2025: In the United States, a life sciences company completed the acquisition of a radioisotope production and distribution business to strengthen vertical integration in radiopharmaceutical supply chains.

✅ December 2025: In Japan, a pharmaceutical group increased investment in a radiopharmaceutical technology company focused on targeted imaging and therapeutic agents.

✅ August 2025: In Europe, a nuclear medicine and diagnostics company acquired a regional radiopharmaceutical manufacturer to expand production capacity and clinical reach across European markets.

Key Players
Novartis | Bayer | Eli Lilly | Jubilant DraxImage | Eckert & Ziegler | Telix Pharmaceuticals | Others

Key Highlights
Novartis holds 28.6% share, driven by its leadership in radiopharmaceuticals, strong oncology pipeline, and global commercialization capabilities.

Bayer holds 22.4% share, supported by established nuclear medicine products, strong R&D investments, and wide adoption in diagnostic and therapeutic applications.

Eli Lilly holds 17.1% share, leveraging its pharmaceutical expertise, expanding oncology portfolio, and strategic investments in advanced imaging and targeted therapies.

Telix Pharmaceuticals holds 13.8% share, driven by rapid growth in targeted radiopharmaceuticals, successful regulatory approvals, and strong clinical trial outcomes.

Jubilant DraxImage holds 9.4% share, supported by radiopharmaceutical manufacturing capabilities, PET imaging agents, and strong presence in diagnostic imaging markets.

Eckert & Ziegler holds 6.2% share, leveraging isotope production expertise, radiopharma components supply, and global distribution network.

Others account for 2.5% share, comprising emerging and regional players developing niche diagnostic and therapeutic radiopharmaceutical solutions.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=radiopharmaceuticals-market?sai-v

Market Drivers
- Rising prevalence of cancer and cardiovascular diseases driving demand for nuclear medicine diagnostics and targeted radiotherapy.

- Growing adoption of molecular imaging techniques such as PET and SPECT for early and accurate disease diagnosis.

- Increasing use of radiopharmaceuticals in personalized and precision medicine approaches.

- Advancements in radioisotope production and imaging technologies improving diagnostic accuracy and therapeutic outcomes.

- Expansion of healthcare infrastructure and nuclear medicine facilities worldwide.

Industry Developments
- Development of novel therapeutic radiopharmaceuticals for oncology, including targeted alpha and beta therapies.

- Expansion of cyclotron and radioisotope production capacity to ensure reliable supply of short-lived isotopes.

- Strategic collaborations between pharmaceutical companies, research institutions, and nuclear medicine centers.

- Increasing clinical trials and regulatory approvals for next-generation radiopharmaceutical agents.

- Integration of AI and advanced imaging analytics to enhance interpretation and treatment planning.

Regional Insights
North America - 41% share: "Driven by advanced nuclear medicine infrastructure, high cancer diagnosis rates, strong R&D investments, and early adoption of innovative radiopharmaceuticals."

Europe - 30% share: "Supported by well-established healthcare systems, strong clinical research networks, and increasing use of molecular imaging technologies."

Asia Pacific - 23% share: "Fueled by expanding healthcare infrastructure, rising cancer incidence, and growing investments in nuclear medicine facilities."

Latin America - 4% share: "Driven by improving access to diagnostic imaging, government healthcare initiatives, and gradual adoption of radiopharmaceuticals."

Middle East & Africa - 2% share: "Supported by investments in specialized medical centers, growing awareness of nuclear medicine, and expanding diagnostic capabilities."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/radiopharmaceuticals-market?sai-v

Key Segments
By Type
Diagnostic radiopharmaceuticals represent the largest segment, driven by widespread use in nuclear imaging for disease detection and monitoring. Therapeutic radiopharmaceuticals are growing rapidly, supported by rising adoption of targeted radionuclide therapies in oncology and personalized medicine.

By Radioisotope
Technetium-99m holds a dominant share, driven by its extensive use in diagnostic imaging procedures. Fluorine-18 represents a significant segment, supported by increasing adoption in PET imaging. Gallium-68 is gaining strong traction, driven by its role in PET diagnostics for oncology and neuroendocrine tumors. Gallium-67 continues to be used in specific diagnostic applications. Iodine-131 accounts for a major therapeutic segment, supported by its long-standing use in thyroid disorders and cancer treatment. Lutetium-177 is witnessing rapid growth, driven by targeted cancer therapies. Yttrium-90 contributes through radioembolization and therapeutic oncology applications. Other radioisotopes include emerging and specialized diagnostic and therapeutic agents.

By Indication
Prostate cancer represents a key indication, driven by increasing use of targeted radiopharmaceutical therapies. Neuroendocrine tumors account for a significant share, supported by theranostic approaches combining diagnosis and treatment. Thyroid cancer and hyperthyroidism remain major segments, driven by established iodine-based therapies. Bone tumors are treated using radiopharmaceuticals for pain palliation and targeted therapy. Myocardial perfusion dominates cardiovascular applications, supported by nuclear imaging for cardiac assessment. Pulmonary and vascular perfusion contribute steadily through diagnostic imaging procedures. Other indications include neurological, renal, and inflammatory disorders.

By End-User
Hospitals dominate the market, driven by availability of nuclear medicine infrastructure and specialized medical professionals. Diagnostic imaging centers represent a significant share, supported by high volumes of outpatient imaging procedures. Ambulatory surgical centers are adopting radiopharmaceuticals steadily, supported by minimally invasive diagnostic and therapeutic workflows. Academic and research institutes contribute through clinical research, trials, and development of novel radiopharmaceuticals. Other end-users include specialty clinics and contract research organizations.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.